NASDAQ:OBSV

ObsEva - OBSV Stock Forecast, Price & News

$0.14

0.00 (-1.48%)

(As of 09/30/2022 03:59 PM ET)

Add

Compare

Today's Range: $0.14
▼
$0.15
50-Day Range: $0.14
▼
$1.62
52-Week Range: $0.13
▼
$3.09

Volume: 16,115 shs
Average Volume: 1.35 million shs
Market Capitalization: $10.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.40

ObsEva MarketRank™ Forecast

Analyst Rating: Hold
2.40 Rating Score
Upside/Downside: 5,900.0% Upside
$8.40 Price Target
Short Interest: Healthy
3.89% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.63) to ($0.23) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

614th out of 1,093 stocks

Pharmaceutical Preparations Industry

292nd out of 548 stocks

3.2

Analyst's Opinion

Consensus Rating
ObsEva has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.40, ObsEva has a forecasted upside of 5,900.0% from its current price of $0.14.
Amount of Analyst Coverage
ObsEva has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.89% of the float of ObsEva has been sold short.
Short Interest Ratio / Days to Cover
ObsEva has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ObsEva has recently decreased by 1.05%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
ObsEva does not currently pay a dividend.
Dividend Growth
ObsEva does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OBSV.

2.7

News and Social Media Coverage

News Sentiment
ObsEva has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for ObsEva this week, compared to 3 articles on an average week.
Search Interest
Only 34 people have searched for OBSV on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added ObsEva to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ObsEva insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 20.12% of the stock of ObsEva is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for ObsEva are expected to grow in the coming year, from ($0.63) to ($0.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ObsEva is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ObsEva is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ObsEva has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ObsEva (NASDAQ:OBSV) Stock

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Stock News Headlines

October 2, 2022 | americanbankingnews.com

StockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV)

September 28, 2022 | americanbankingnews.com

ObsEva SA (NASDAQ:OBSV) Receives Consensus Rating of "Hold" from Analysts

September 24, 2022 | americanbankingnews.com

ObsEva (NASDAQ:OBSV) Research Coverage Started at StockNews.com

September 15, 2022 | baystreet.ca

ObsEva Flat on Restructuring Initiatives - Baystreet.ca

September 13, 2022 | finance.yahoo.com

After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff

September 13, 2022 | globenewswire.com

ObsEva Announces Progress on Restructuring Initiatives - GlobeNewswire

September 11, 2022 | reuters.com

OBSV.O - Obseva SA | Stock Price & Latest News | Reuters

September 10, 2022 | reuters.com

OBSV.N - Obseva SA | Stock Price & Latest News | Reuters

September 7, 2022 | finance.yahoo.com

This Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring'

August 31, 2022 | streetinsider.com

Hot Penny Stocks For Your Buy List in September? 3 to Watch - StreetInsider.com

August 31, 2022 | uk.investing.com

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know By Benzinga - Investing.com UK

August 25, 2022 | businesswire.com

Global Female Infertility Drug Pipeline Market Report 2022: Insights about 12 Pipelines Drugs Including Emerging Drugs - OXO-001 (Oxolife) & Nolasiban (ObsEva) - ResearchAndMarkets.com - Business Wire

August 23, 2022 | seekingalpha.com

ObsEva stock dips on Nasdaq non-compliance notice - Seeking Alpha

August 22, 2022 | globenewswire.com

ObsEva Receives Nasdaq Non-Compliance Notice - GlobeNewswire

August 22, 2022 | finance.yahoo.com

ObsEva Receives Nasdaq Non-Compliance Notice

August 18, 2022 | benzinga.com

ObsEva: Q2 Earnings Insights - Benzinga

August 17, 2022 | globenewswire.com

ObsEva Files Second Quarter 2022 Financial Statements - GlobeNewswire

August 17, 2022 | finance.yahoo.com

ObsEva Files Second Quarter 2022 Financial Statements

August 3, 2022 | nasdaq.com

All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy - Nasdaq

August 3, 2022 | finance.yahoo.com

All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy

August 2, 2022 | investing.com

ObsEva SA Tops Q2 EPS by 5c By Investing.com - Investing.com

August 2, 2022 | ca.investing.com

ObsEva SA Tops Q2 EPS by 5c By Investing.com - Investing.com Canada

August 2, 2022 | streetinsider.com

ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing - StreetInsider.com

August 1, 2022 | globenewswire.com

ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing - GlobeNewswire

July 29, 2022 | streetinsider.com

ObsEva Announces Management Change - StreetInsider.com

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Company Calendar

Last Earnings: 8/17/2022
Today: 10/03/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OBSV
CUSIP: N/A
CIK: 1685316
Web: www.obseva.com
Phone: (122) 552-3840
Fax: N/A
Employees: 48
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.40
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +5,900.0%
Consensus Rating: Hold
Rating Score (0-4): 2.40
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,380,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -173.60%
Return on Assets: -53.86%

Debt

Debt-to-Equity Ratio: 1.18
Current Ratio: 2.98
Quick Ratio: 2.98

Sales & Book Value

Annual Sales: $20.11 million
Price / Sales: 0.54
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.41 per share
Price / Book: 0.34

Miscellaneous

Outstanding Shares: 77,971,000
Free Float: N/A
Market Cap: $10.92 million
Optionable: Not Optionable
Beta: 0.37

Key Executives

Mr. Brian O'Callaghan (Age 53)
CEO & Director
Comp: $1.12M

Dr. Ernest Loumaye M.D. (Age 70)
OB/GYN, Ph.D., Co-Founder & Director
Comp: $62k

Dr. Jean-Pierre Gotteland Ph.D. (Age 57)
Chief Scientific Officer and Head of R&D

Mr. Fabien Lefebvre de Ladonchamps (Age 43)
Chief Admin. Officer

Mr. Clive Bertram (Age 54)
Chief Commercial Officer

Mr. Luigi Marro (Age 56)
Chief Transformation Officer

Mr. William Michael Brown (Age 39)
Chief Financial Officer

Ms. Delphine Renaud
Personal Assistant to the CSO and Head of R&D

Ms. Katja Buhrer (Age 40)
Chief Strategy Officer

Ms. Brandi Howard Ph.D.
Chief Clinical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OBSV Stock - Frequently Asked Questions

Should I buy or sell ObsEva stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OBSV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OBSV, but not buy additional shares or sell existing shares.
View OBSV analyst ratings or view top-rated stocks.
What is ObsEva's stock price forecast for 2022?: 5 brokers have issued 1 year target prices for ObsEva's shares. Their OBSV share price forecasts range from $1.00 to $12.00. On average, they anticipate the company's stock price to reach $8.40 in the next twelve months. This suggests a possible upside of 5,900.0% from the stock's current price.
View analysts price targets for OBSV or view top-rated stocks among Wall Street analysts.
How have OBSV shares performed in 2022?: ObsEva's stock was trading at $1.99 on January 1st, 2022. Since then, OBSV shares have decreased by 93.0% and is now trading at $0.14.
View the best growth stocks for 2022 here.
When is ObsEva's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our OBSV earnings forecast.
How were ObsEva's earnings last quarter?: ObsEva SA (NASDAQ:OBSV) posted its quarterly earnings results on Wednesday, August, 17th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.06. The business had revenue of $2.61 million for the quarter, compared to analyst estimates of $0.01 million.

What other stocks do shareholders of ObsEva own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).
When did ObsEva IPO?: (OBSV) raised $98 million in an initial public offering on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.
What is ObsEva's stock symbol?: ObsEva trades on the NASDAQ under the ticker symbol "OBSV."
How do I buy shares of ObsEva?: Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ObsEva's stock price today?: One share of OBSV stock can currently be purchased for approximately $0.14.
How much money does ObsEva make?: ObsEva (NASDAQ:OBSV) has a market capitalization of $10.92 million and generates $20.11 million in revenue each year. The company earns $-58,380,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.
How can I contact ObsEva?: ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The official website for the company is www.obseva.com. The company can be reached via phone at (122) 552-3840 or via email at ir@obseva.ch.

This page (NASDAQ:OBSV) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ObsEva - OBSV Stock Forecast, Price & News

ObsEva MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows